Αρχική World News First-Line Treatment with Encorafenib Plus Cetuximab Plus mFOLFOX6 Significantly Improves ORR in... World News First-Line Treatment with Encorafenib Plus Cetuximab Plus mFOLFOX6 Significantly Improves ORR in Patients with BRAF V600E-mutated mCRC Από Ogkologos - 17 Φεβρουαρίου, 2025 969 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BREAKWATER study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Dad Is Making Baby Giggle, But When He Makes A Sheep... 21 Μαΐου, 2019 Keeping progress in oncology on the agenda: ESMO honours recipients of... 3 Δεκεμβρίου, 2020 A Subgroup of Patients with a Very Poor Prognosis Diffuse Intrinsic... 12 Μαΐου, 2026 EMA Recommends Extension of Indications for Durvalumab 27 Ιουλίου, 2020 Φόρτωση περισσοτέρων HOT NEWS FDA Grants Accelerated Approval to fam-Trastuzumab Deruxtecan-nxki for HER2-Mutated NSCLC Obesity May Help Tumors Survive and Grow, Mouse Study Suggests Talking About Sexual Health Concerns With Your Cancer Care Team: How... FDA Approves Atezolizumab for BRAF V600 Mutation Positive Unresectable or Metastatic...
